# Safety and Efficacy of CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy to Treat Refractory Viral Keratitis

> **NCT04560790** · NA · COMPLETED · sponsor: **Shanghai BDgene Co., Ltd.** · enrollment: 3 (actual)

## Conditions studied

- Viral Keratitis
- Blindness Eye
- Herpes Simplex Virus Infection
- Cornea

## Interventions

- **DRUG:** BD111 Adult single group Dose

## Key facts

- **NCT ID:** NCT04560790
- **Lead sponsor:** Shanghai BDgene Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-04
- **Primary completion:** 2022-07-05
- **Final completion:** 2022-07-05
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2022-08-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04560790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04560790, "Safety and Efficacy of CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy to Treat Refractory Viral Keratitis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04560790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*